Wolwo Pharma: Application for clinical trial of dermatitis diagnostic patch 02 has been accepted
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, Wolwo Pharma announced that the company has received the "Acceptance Notice" issued by the National Medical Products Administration, and the clinical trial application for the "Dermatitis Diagnostic Patch 02" submitted by the company has been officially accepted. The relevant indications are: for patch testing, to assist in the diagnosis of allergic contact dermatitis related to sensitization by carbamates, p-phenylenediamine, and formaldehyde
According to the Zhitong Finance APP, Wolwo Pharma (300357.SZ) announced that the company has received the "Acceptance Notice" issued by the National Medical Products Administration, and the clinical trial application for the "Dermatitis Diagnostic Patch 02" submitted by the company has been officially accepted. The relevant indications are: for patch testing, to assist in the diagnosis of allergic contact dermatitis related to sensitization by carbamates, p-phenylenediamine, and formaldehyde